Labcorp Holdings Inc. (LH) Financials
Key financial figures for Labcorp Holdings Inc. (Q3 2026).
Labcorp Q3 2026 revenue rose 6.9% to $3.81B and adjusted EPS rose 14.5% to $4.78; full-year revenue growth and adjusted EPS guidance raised. Revenue was $3,810.0M, up 6.9% from $3,563.5M (organic +5.5%, acquisitions net of divestitures +1.5%, foreign exchange -0.1%). Adjusted EPS was $4.78 vs $4.18 (+14.5%); GAAP diluted EPS was $3.22 vs $3.12 (+3.3%). Diagnostics Laboratories revenue was $2,948.9M, up 6.5% (organic +4.4%, acquisitions +2.2%); adjusted operating margin 16.7% vs 16.3%. Requisition volume rose 4.8% in total (3.1% organic) and price/mix added 1.7% (1.3% organic). On the outlook: 2026 full-year guidance raised (foreign exchange as of September 30, 2026): enterprise revenue $14,779M to $14,887M, growth 5.9% to 6.7% (previously $14,710M to $14,827M, 5.4% to 6.3%); Diagnostics Laboratories revenue $11,475M to $11,551M, growth 5.5% to 6.2% (previously $11,450M to $11,532M, 5.3% to 6.0%); Biopharma Laboratory Services revenue $3,328M to $3,358M, growth 7.4% to 8.4% (previously $3,269M to $3,300M, 5.5% to 6.5%); adjusted EPS $18.30 to $18.70 (previously $18.10 to $18.55); free cash flow $1,240M to $1,360M, unchanged. Enterprise guidance includes the estimated impact of currently anticipated acquisitions, share repurchases and dividends. Figures are for Q3 2026, as LabCorp Holdings Inc. reported them.
- Revenue
- $3.8B
- Net Income
- $263M
- EPS
- $3.24
- Total Assets
- $18.9B
- Operating Cash Flow
- $564M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $3.8B | $263M | $3.22 | 10.55% | $412M |
| Q2 FY2026 | $3.7B | $299M | $3.64 | 12.1% | $314M |
| Q1 FY2026 | $3.5B | $278M | $3.35 | 10.95% | $71M |
| Q4 FY2025 | $3.5B | $165M | $1.98 | 10.87% | $490M |
| Q3 FY2025 | $3.6B | $261M | $3.12 | 11.13% | $281M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $14.0B | $877M | $10.46 | 10.87% | $1.2B |
| FY2024 | $13.0B | $746M | $8.84 | 8.35% | $1.1B |
| FY2023 | $12.2B | $418M | $4.77 | 5.97% | $874M |
Frequently asked questions
What was LabCorp Holdings Inc.'s revenue last quarter?
LabCorp Holdings Inc. reported revenue of $3.81 billion for Q3 FY2026, up 6.9% from the same period a year earlier.
Is LabCorp Holdings Inc. profitable?
Yes. LabCorp Holdings Inc. reported net income of $262.8 million for Q3 FY2026, a net margin of 6.9% on revenue.
How has LabCorp Holdings Inc.'s margin trended?
Operating margin was 10.55% in Q3 FY2026, compared with 11.13% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did LabCorp Holdings Inc. generate?
LabCorp Holdings Inc. generated free cash flow of $412.2 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Labcorp Holdings Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.